Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.5K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

1.2K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The hybrid strategy of left atrial appendage closure on top of anticoagulation in patients with prior anticoagulation failure: a multicenter study.

Polish archives of internal medicine·2026
Same author

Sirtuins in Medicine: Multifaceted Roles in Physiological Processes and Cardiovascular Diseases.

Biomolecules·2026
Same author

Investigating the risk of obesity in European night shift workers: a study protocol for cross-sectional and mechanistic studies in the SHIFT2HEALTH Project.

Obesity facts·2026
Same author

Development and implementation of ICF-based functioning assessment in polish medical rehabilitation: a comprehensive system‑level pilot study.

BMC health services research·2026
Same author

Factors influencing the risk of cardiovascular complications following COVID-19 - clinical implications. The LATE-COVID study.

Archives of medical science : AMS·2026
Same author

Evaluation of Intra-Amniotic Infection Detection Based on Available Diagnostic Methods.

Medicina (Kaunas, Lithuania)·2025

Related Experiment Video

Updated: Apr 16, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.5K

Renal denervation--hypes and hopes.

Joanna Lewek1, Krzysztof Kaczmarek1, Evgeniy Pokushalov2

  • 1Department of Electrocardiology, Sterling Regional Heart Disease Center, Medical University, Lodz, Poland.

Cardiovascular Therapeutics
|March 20, 2015
PubMed
Summary

Renal denervation (RDN) shows potential for treating resistant hypertension and other conditions by modulating the nervous system. However, recent trial results question its effectiveness, necessitating further research into improved techniques.

Keywords:
Autonomic nervous systemrenal denervationresistant hypertension

More Related Videos

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

892
Novel Approach for Simultaneous Recording of Renal Sympathetic Nerve Activity and Blood Pressure with Intravenous Infusion in Conscious, Unrestrained Mice.
11:08

Novel Approach for Simultaneous Recording of Renal Sympathetic Nerve Activity and Blood Pressure with Intravenous Infusion in Conscious, Unrestrained Mice.

Published on: February 14, 2018

11.2K

Related Experiment Videos

Last Updated: Apr 16, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.5K
Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

892
Novel Approach for Simultaneous Recording of Renal Sympathetic Nerve Activity and Blood Pressure with Intravenous Infusion in Conscious, Unrestrained Mice.
11:08

Novel Approach for Simultaneous Recording of Renal Sympathetic Nerve Activity and Blood Pressure with Intravenous Infusion in Conscious, Unrestrained Mice.

Published on: February 14, 2018

11.2K

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Nephrology

Background:

  • Resistant hypertension poses a significant clinical challenge.
  • Catheter-based renal denervation (RDN) emerged as a minimally invasive treatment targeting autonomic nervous system modulation.
  • Initial studies suggested RDN could lower blood pressure and modify risk factors.

Purpose of the Study:

  • To evaluate the efficacy of renal denervation in resistant hypertension.
  • To explore potential benefits of RDN in other sympathetic nervous system-related conditions.
  • To discuss advancements in RDN techniques.

Main Methods:

  • Review of experimental and clinical trials on renal denervation.
  • Analysis of results from the randomized Symplicity HTN-3 trial.
  • Consideration of novel electrode designs and electrophysiological approaches for RDN.

Main Results:

  • The Symplicity HTN-3 trial failed to demonstrate a significant blood pressure reduction with RDN at six months.
  • This outcome tempered initial enthusiasm for RDN in resistant hypertension.
  • RDN may still hold promise for conditions with increased sympathetic tone, such as heart failure and arrhythmias.

Conclusions:

  • The efficacy of current RDN procedures for resistant hypertension remains uncertain following recent trial data.
  • Further investigation into adapted RDN techniques and technologies is warranted.
  • RDN may offer therapeutic benefits for a broader range of cardiovascular conditions linked to sympathetic overactivity.